

# AMIDEBIO

## *Update on Novel Pumpable Glucagon for Treating Hyperinsulinism*


**Michael H. B. Stowell, Ph.D.**  
**Founder and CSO**  
**September 7 2019**




# Glucagon as Treatment

---

- Directly address HI
- Targets a Normal Physiological Pathway
- Reverses Effects of Increased Insulin



# The Problem



**FIBRILLATION**



**INACTIVATION**

# The Solution

---

Low immunogenicity solution stable glucagon suitable for a wearable pump format.

Solution Stable to 40°C

Minimized immunogenicity

**Automated dosing**




Low cost manufacturing

No toxic additives

**Wearable for home use**


AmideBio has designed and produced more than 50 glucagon analogues with solution stability at 40°C up to 3 months.

# The Stability Data




- From 2 to 15 times more stable than glucagon with maximal stabilities greater than 3 months.

# The Activity Data (SUR1 KO Mice)



- In Vivo activity similar to native glucagon

# The Immunogenicity Data



- **Analogs designed to avoid the hotspot of immunogenicity**

# The Timeline

---

DISCOVERY 50+ CANDIDATES

**COMPLETED**

IN VITRO ACTIVITY STUDIES

**COMPLETED**

IN VIVO EFFICACY STUDIES

**COMPLETED**

GLP TOX STUDIES

**2019-2020**

SUBMISSION OF IND

**Q4 2020**

CLINICAL TRIALS

**2021**



# The People and Dollars

---



**Diva D. De León-Crutchlow, MD**  
**Jinghua Chai, Ph.D.**



**Stephen Eisenberg, Ph.D.**  
**Yanyu Peng, M.S.**  
**Elizabeth Schanuel, B.S.**

